U.S. Pharmaceuticals & Biotech High ROE Growth Engines

Exelixis

Market Cap: US$10.2b

An oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.

ACADIA Pharmaceuticals

Market Cap: US$4.3b

A biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States.

Agios Pharmaceuticals

Market Cap: US$2.2b

A biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States.

CureVac

Market Cap: US$1.2b

A biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA).

Niagen Bioscience

Market Cap: US$801.6m

Operates as a bioscience company engages in developing healthy aging products.

SIGA Technologies

Market Cap: US$623.0m

A commercial-stage pharmaceutical company, focuses on the health security market in the United States.

Abeona Therapeutics

Market Cap: US$359.5m

A clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases.

CytomX Therapeutics

Market Cap: US$329.8m

Operates as an oncology-focused biopharmaceutical company that focuses on developing novel conditionally activated biologics localized to the tumor microenvironment.

Puma Biotechnology

Market Cap: US$251.3m

A biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally.

Coherus Oncology

Market Cap: US$136.0m

A biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States.